Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial

Click here to view online. Add this email to your safelist.

AstraZeneca logo

Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial

12 May 2026

Positive results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) 1 receptor agonist, met its composite primary endpoint, demonstrating a statistically significant and clinically meaningful normalisation of albumin-adjusted serum calcium (sCa) levels and independence from active vitamin D and oral calcium supplements in adults with chronic hypoparathyroidism (HypoPT) at week 24.

Read more  Read more

RSS Feed  RSS Feed Twitter/X  Follow us on X LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2026

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.